Amgen (AMGN) Competitors $293.43 +3.45 (+1.19%) Closing price 04:00 PM EasternExtended Trading$293.07 -0.36 (-0.12%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AMGN vs. GILD, VRTX, REGN, ALNY, BIIB, UTHR, INCY, NBIX, EXEL, and BMRNShould you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "biotechnology" industry. Amgen vs. Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Incyte Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings. Does the media favor AMGN or GILD? In the previous week, Amgen had 4 more articles in the media than Gilead Sciences. MarketBeat recorded 56 mentions for Amgen and 52 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.33 beat Amgen's score of 1.20 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 46 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gilead Sciences 37 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, AMGN or GILD? Amgen has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Do analysts recommend AMGN or GILD? Amgen currently has a consensus target price of $309.22, suggesting a potential upside of 5.38%. Gilead Sciences has a consensus target price of $110.55, suggesting a potential upside of 0.41%. Given Amgen's higher probable upside, equities research analysts plainly believe Amgen is more favorable than Gilead Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 2 Sell rating(s) 12 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.38Gilead Sciences 0 Sell rating(s) 9 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.78 Does the MarketBeat Community favor AMGN or GILD? Gilead Sciences received 926 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 76.84% of users gave Gilead Sciences an outperform vote while only 71.71% of users gave Amgen an outperform vote. CompanyUnderperformOutperformAmgenOutperform Votes155971.71% Underperform Votes61528.29% Gilead SciencesOutperform Votes248576.84% Underperform Votes74923.16% Which has higher valuation & earnings, AMGN or GILD? Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmgen$34.13B4.62$4.09B$10.9626.77Gilead Sciences$28.74B4.77$480M$4.7523.18 Is AMGN or GILD more profitable? Amgen has a net margin of 12.24% compared to Gilead Sciences' net margin of 1.67%. Amgen's return on equity of 176.32% beat Gilead Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Amgen12.24% 176.32% 11.71% Gilead Sciences 1.67%31.63%10.38% Is AMGN or GILD a better dividend stock? Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Gilead Sciences pays an annual dividend of $3.16 per share and has a dividend yield of 2.9%. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences pays out 66.5% of its earnings in the form of a dividend. Amgen has increased its dividend for 14 consecutive years and Gilead Sciences has increased its dividend for 10 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. Do institutionals & insiders hold more shares of AMGN or GILD? 76.5% of Amgen shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.8% of Amgen shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryAmgen beats Gilead Sciences on 12 of the 22 factors compared between the two stocks. Get Amgen News Delivered to You Automatically Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMGN vs. The Competition Export to ExcelMetricAmgenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$157.78B$3.10B$5.57B$8.67BDividend Yield3.32%1.59%5.27%4.19%P/E Ratio38.8633.8227.2020.16Price / Sales4.62476.37412.92162.04Price / Cash9.98168.6838.2534.64Price / Book26.853.497.114.72Net Income$4.09B-$72.35M$3.23B$247.80M7 Day Performance1.33%10.49%4.61%3.36%1 Month Performance10.37%24.23%13.35%9.71%1 Year Performance-3.71%-15.55%31.75%14.41% Amgen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMGNAmgen4.3367 of 5 stars$293.43+1.2%$309.22+5.4%-4.9%$157.78B$34.13B38.8625,200Positive NewsAnalyst RevisionGILDGilead Sciences4.7644 of 5 stars$108.88-1.1%$110.55+1.5%+74.7%$135.25B$28.74B293.8617,000Trending NewsAnalyst RevisionGap DownVRTXVertex Pharmaceuticals4.2859 of 5 stars$443.48+0.3%$515.04+16.1%-7.6%$113.96B$11.10B-201.724,800Positive NewsREGNRegeneron Pharmaceuticals4.8317 of 5 stars$494.33+0.8%$847.40+71.4%-48.4%$53.34B$14.09B12.9111,900Analyst ForecastHigh Trading VolumeALNYAlnylam Pharmaceuticals3.9381 of 5 stars$303.67-0.3%$319.17+5.1%+99.0%$39.58B$2.35B-139.902,000BIIBBiogen4.7978 of 5 stars$130.93+0.9%$191.30+46.1%-40.5%$19.17B$9.82B11.698,720Positive NewsUTHRUnited Therapeutics4.9653 of 5 stars$324.08+1.6%$393.00+21.3%+19.4%$14.62B$2.99B14.23980Trending NewsInsider TradeAnalyst RevisionGap DownINCYIncyte4.2963 of 5 stars$65.39+0.5%$73.60+12.6%+18.1%$12.65B$4.41B242.142,320Positive NewsNBIXNeurocrine Biosciences4.9489 of 5 stars$124.47+1.2%$162.00+30.2%-6.8%$12.32B$2.41B37.841,200Analyst RevisionEXELExelixis4.5521 of 5 stars$42.77-0.6%$38.94-9.0%+96.2%$11.66B$2.30B24.161,220Positive NewsBMRNBioMarin Pharmaceutical4.8958 of 5 stars$57.29-1.3%$93.45+63.1%-29.5%$10.99B$2.95B26.043,080Positive NewsAnalyst Revision Related Companies and Tools Related Companies GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors UTHR Competitors INCY Competitors NBIX Competitors EXEL Competitors BMRN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMGN) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored50-year legend: Here’s exact day stocks will crashGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amgen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
